Is GHRP-2 stronger than ipamorelin?

GHRP-2 produces a stronger GH response than ipamorelin in most comparative studies. However, ipamorelin is preferred in clinical practice because it achieves meaningful GH release without the cortisol, prolactin, and appetite side effects that GHRP-2 causes.

Is GHRP-2 FDA-approved?

GHRP-2 is not FDA-approved in the United States. It is approved in Japan as pralmorelin for GH deficiency diagnosis. It is on the FDA Category 2 compounding list, meaning it can be compounded with a valid prescription under specific conditions.

What are the main side effects of GHRP-2?

The primary side effects are appetite stimulation, cortisol elevation, and prolactin increase. These are dose-dependent and less pronounced than GHRP-6 but more significant than ipamorelin. Facial flushing and water retention can occur at higher doses.

Can GHRP-2 be combined with CJC-1295?

Yes. GHRP-2 and GHRH analogs like CJC-1295 produce synergistic GH release through complementary receptor pathways. This combination is widely used in clinical protocols, though the side effect profile of GHRP-2 still applies.

Does GHRP-2 help with muscle growth?

GHRP-2 elevates growth hormone, which is known to support lean mass preservation and lipolysis. However, controlled trials specifically measuring body composition outcomes with GHRP-2 are limited. The GH elevation is well-documented; the downstream body composition effects are inferred rather than directly demonstrated in controlled trials.

What does the research show about: Pihoker et al. (1997): Demonstrated potent GH release in both children and adult?

Pihoker et al. (1997): Demonstrated potent GH release in both children and adults, establishing GHRP-2 as one of the most effective GH secretagogues.. Foundational human pharmacology data that led to diagnostic approval in Japan

What does the research show about: Laferrere et al. (2005): Showed enhanced GH response even in obese subjects, a p?

Laferrere et al. (2005): Showed enhanced GH response even in obese subjects, a population that typically has blunted GH release.. Suggests GHRP-2 may partially overcome obesity-related GH suppression

What does the research show about: Comparative studies consistently rank GHRP-2 among the highest GH responders in ?

Comparative studies consistently rank GHRP-2 among the highest GH responders in the synthetic secretagogue class, with potency comparable to or exceeding hexarelin.. Positions GHRP-2 as a potency benchmark in GH secretagogue pharmacology

reviewed april 2026|next review october 2026|88 physicians psi has verified|255 published studies

GHRP-2

GHRP-2 (pralmorelin) is a synthetic hexapeptide growth hormone secretagogue with regulatory approval in Japan for GH deficiency diagnosis, the deepest human evidence base in the GH secretagogue class (61 human studies), and one of the strongest documented GH responses.

Evidence landscape: 255 published studies

255 published items. 61 human studies and 121 animal studies. The deepest human evidence base of any GH secretagogue, including the only regulatory approval in the class outside of tesamorelin.

61 Human
121 Animal
18 Reviews
55 Other research

Approved in Japan as pralmorelin for growth hormone deficiency diagnosis - the only GH secretagogue with regulatory approval outside of tesamorelin.

61 human studies - the deepest human evidence base of any GH secretagogue.

Elevates cortisol, prolactin, and appetite alongside GH through ghrelin receptor co-activation. Less pronounced than GHRP-6, more than ipamorelin.

PSI Assessment

Among all synthetic growth hormone secretagogues, GHRP-2 holds a distinction that no other GHRP shares: regulatory approval in Japan as pralmorelin for growth hormone deficiency diagnosis. With 61 human studies, it has the deepest human evidence base in the GH secretagogue class. The GH response is among the strongest documented, but unlike the selective profile of ipamorelin, GHRP-2 also elevates cortisol, prolactin, and appetite through ghrelin receptor co-activation.

Regulatory approval in Japan for GH deficiency diagnosis. 61 human studies, the deepest evidence base in the GH secretagogue class.

The mechanism is ghrelin receptor (GHS-R1a) agonism through the PLC/IP3/calcium pathway, which is complementary to the cAMP pathway used by GHRH analogs like CJC-1295. This complementary signaling is the pharmacological rationale for combining GHRPs with GHRH analogs. The Japan diagnostic approval as pralmorelin provides a level of clinical validation that most research peptides lack.

What the evidence supports

GHRP-2 is approved in Japan as pralmorelin for GH deficiency diagnosis, the only GH secretagogue with regulatory approval outside of tesamorelin. With 61 human studies, it has the deepest human evidence base in the class. The GH response is dose-dependent, reproducible, and among the strongest documented. The non-selective hormonal profile (cortisol, prolactin, appetite) is well-characterized.

What is not yet established

Whether the GH elevation translates to meaningful body composition or functional outcomes in controlled trials. Long-term safety of the non-selective hormonal profile. How the trade-off between potency and selectivity compares to ipamorelin for clinical applications.

Research Evidence

The findings below cover the Japan regulatory approval, the depth of human evidence, and the non-selective profile that defines the clinical trade-off.

Evidence by condition

Evidence dimensions across GHRP-2's investigated conditions. GH stimulation has the deepest evidence with regulatory validation.

Condition	Mechanism	Animal evidence	Human evidence	Replication
GH Stimulation
Body Composition
Appetite Stimulation
Cardiac Research
Sleep

GHRP-2 is approved in Japan as pralmorelin for GH deficiency diagnosis. This regulatory approval provides clinical validation that most research peptides lack and reflects the reproducibility and reliability of the GH-releasing response.

The diagnostic approval is based on the compound's ability to reliably provoke a GH pulse for clinical assessment. It is the only GHRP with this level of regulatory validation outside of tesamorelin.

With 61 human studies, GHRP-2 has the deepest human evidence base in the GH secretagogue class. The GH response is dose-dependent, reproducible, and among the strongest documented. Synergistic GH release with GHRH analogs is consistently reproduced.

The depth of human pharmacology data exceeds all other GHRPs. Most evidence is pharmacological (GH response measurement) rather than clinical outcome-based.

The non-selective hormonal profile includes appetite stimulation, cortisol elevation, and prolactin increase - all dose-dependent. These effects are less pronounced than GHRP-6 but more significant than ipamorelin, which is why ipamorelin is often the preferred clinical choice.

The trade-off between GH potency and selectivity is the central clinical question. For most applications, the selectivity advantage of ipamorelin outweighs the potency advantage of GHRP-2.

61 Human|121 Animal|18 Reviews

View all 255 indexed studies

How GHRP-2 Works

GHRP-2 (D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide that binds the ghrelin receptor (GHS-R1a) with high affinity, stimulating GH release through a pathway complementary to GHRH.

Your pituitary gland releases growth hormone in pulses throughout the day, with the largest pulses occurring during deep sleep. GHRP-2 triggers an additional GH pulse by activating the same receptor that the hunger hormone ghrelin uses. The result is a strong burst of growth hormone release. The downside is that because it uses the ghrelin receptor, it also triggers appetite, cortisol (a stress hormone), and prolactin alongside the GH release.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

GHRP-2 activates GHS-R1a in the anterior pituitary and hypothalamus. It stimulates GH release through the phospholipase C/IP3/calcium pathway, complementary to the cAMP/PKA pathway used by GHRH analogs. It suppresses somatostatin tone, amplifying the GH pulse. Cortisol elevation occurs through ACTH stimulation via CRH neurons. Prolactin elevation involves dopaminergic pathway modulation. The complementary signaling with GHRH is the pharmacological basis for combination protocols.

What is GHRP-2 being studied for?

Researchers are studying GHRP-2 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for GHRP-2 overall. This means a compound can have human studies for one condition but only animal data for another.

GH Stimulation

·Human Trials

GHRP-2 produces one of the strongest GH responses of any synthetic secretagogue in human studies. Approved in Japan as pralmorelin for GH deficiency diagnosis based on the reliability and reproducibility of the GH response.

Limitations: GH stimulation is well-documented, but whether the GH elevation translates to clinical outcomes (body composition, recovery) has not been established in controlled outcome trials.

Body Composition

·Animal Studies

The rationale for body composition effects is based on the well-documented GH elevation. Direct body composition outcome data from controlled GHRP-2 trials is limited.

Limitations: Controlled body composition outcome data is limited. The appetite stimulation effect may partially counteract fat loss benefits in practice.

Appetite Stimulation

·Animal Studies

GHRP-2 significantly increases appetite through ghrelin receptor activation. This effect is less pronounced than GHRP-6 but more significant than ipamorelin.

Limitations: Whether appetite stimulation can be therapeutically useful in appetite-loss conditions has not been studied in controlled trials.

Cardiac Research

·Animal Studies

Animal data suggests GHRP-2 may have cardioprotective effects independent of GH release, similar to findings with other GHRPs.

Limitations: Cardiac research for GHRP-2 specifically is limited. Most cardioprotective data comes from GHRP-6 and hexarelin studies. Human cardiac outcome data does not exist.

Sleep

·Preclinical

GH secretagogues are associated with enhanced slow-wave sleep. GHRP-2 may influence sleep architecture through its GH-releasing activity.

Limitations: No controlled trials have specifically studied GHRP-2's effects on sleep architecture. Evidence is inferential from GH physiology.

Safety and Regulatory Status

FDA Status: Not FDA-approved in the United States.

Japan Approval: Approved in Japan as pralmorelin for GH deficiency diagnosis.

Availability: On the FDA Category 2 list, meaning licensed pharmacies cannot currently compound it - the compound is restricted from preparation by compounding pharmacies.

The most common effects beyond GH release are appetite stimulation, cortisol elevation, and prolactin increase. These are dose-dependent and less pronounced than with GHRP-6. Serious adverse events in published studies are rare.

Peptide Structure

Technical molecular data for researchers and clinicians.

Questions and Comparisons

Questions the evidence raises for a GHRP-2 discussion.

Comparison and Related Research

GHRP-2 is most often compared with ipamorelin (selective, fewer studies), GHRP-6 (original, deeper animal base), and hexarelin (strongest potency, cardiac mechanism).

Head-to-head comparisons

Full research comparisons covering GHRP-2 and another peptide side by side.

GHRP-2 vs Ipamorelin

GHRP-2 produces a stronger GH pulse but raises cortisol and appetite. Ipamorelin is selective with minimal off-target effects. Evidence-graded comparison.

View full comparison

Related compounds

Ipamorelin GHRP-6 Hexarelin CJC-1295 MK-677

Frequently Asked Questions

References

Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.

1.Foundational study characterizing the mechanism by which GHRP stimulates growth hormone release from pituitary cells. The research demonstrated that GHRP acts through a pathway distinct from GHRH, establishing the basis for the growth hormone secretagogue receptor concept.Bowers CY et al., 1991 in Biochem Biophys Res Commun. View on PubMed
2.Landmark discovery identifying ghrelin as the endogenous ligand for the growth hormone secretagogue receptor. This finding provided essential context for understanding how synthetic GHRPs like GHRP-2 activate the same receptor system that the body uses naturally to regulate GH release.Kojima M et al., 1999 in Nature. View on PubMed
3.Evaluated long-term oral GHRP-2 in children with GH deficiency. The study measured appetite changes, body weight, and GH responses over an extended treatment period, providing rare sustained-dosing data in a pediatric population.Mericq V et al., 2003 in J Pediatr Endocrinol Metab. View on PubMed
4.Demonstrated that GHRP-2 increases food intake and appetite in healthy adult males, confirming that the compound activates appetite pathways in the same manner as the body's natural ghrelin signaling system.Laferrere B et al., 2005 in J Clin Endocrinol Metab. View on PubMed

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.